Werewolf Therapeutics (NASDAQ:HOWL) Issues Earnings Results

Werewolf Therapeutics (NASDAQ:HOWL) released its quarterly earnings results on Friday. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.36, FiscalAI reports. The business had revenue of $21.00 million during the quarter.

Werewolf Therapeutics Stock Down 29.4%

NASDAQ:HOWL traded down $0.15 during trading hours on Friday, hitting $0.35. 2,949,032 shares of the stock traded hands, compared to its average volume of 732,900. The company has a market cap of $17.16 million, a price-to-earnings ratio of -0.28 and a beta of 0.30. Werewolf Therapeutics has a 1 year low of $0.27 and a 1 year high of $2.38. The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.60.

Analyst Ratings Changes

HOWL has been the subject of a number of recent research reports. Wall Street Zen raised shares of Werewolf Therapeutics to a “sell” rating in a research report on Saturday. Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus price target of $3.75.

Insider Buying and Selling at Werewolf Therapeutics

In related news, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total transaction of $145,918.85. Following the completion of the transaction, the insider directly owned 303,719 shares of the company’s stock, valued at $106,301.65. This represents a 57.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,634,670 shares of company stock worth $1,751,888 over the last 90 days. Insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. Bridgeway Capital Management LLC raised its position in shares of Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after buying an additional 62,414 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics in the second quarter worth $409,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after buying an additional 221,766 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.